|Change:||-$0.07 ( -1.98% )||52Wk High:||$6.98|
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company's product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.
|15 Biggest Mid-Day Losers For Thursday||03/23/2017|
|15 Biggest Mid-Day Gainers For Wednesday||03/22/2017|
|Mid-Afternoon Market Update: Crude Oil Down 1.5%; Canadian Solar Shares Drop On Earnings Miss||03/21/2017|
|15 Biggest Mid-Day Losers For Monday||03/20/2017|
|A Peek Into The Markets: U.S. Stock Futures Edge Lower; Crude Oil Drops||03/20/2017|
|15 Biggest Mid-Day Gainers For Friday||03/17/2017|
|Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix||02/07/2017||TheStreet|
|These 5 Stocks Under $10 Could Get Hot Soon||01/27/2017||TheStreet|
|Mid-Afternoon Market Update: Crude Oil Up 1.2%; Progress Software Shares Plunge||01/17/2017|
Do you have a hot tip on a stock? Share it with our community. Get started by entering the company name or symbol below.